Viking Therapeutics (VKTX) Amortization of Deferred Charges (2019 - 2022)

Viking Therapeutics has disclosed Amortization of Deferred Charges across 4 years of filings, most recently posting $77000.0 for Q1 2022.

• Amortization of Deferred Charges for Q1 2022 came in at $77000.0, up 6.94% year-over-year; the trailing twelve-month figure through Mar 2022 was $301000.0 (up 7.12% YoY), and the FY2021 annual result was $296000.0, up 6.86% from the prior year.
• Amortization of Deferred Charges came in at $77000.0 for Q1 2022 at Viking Therapeutics, up from $76000.0 in the prior quarter.
• In the past five years, Amortization of Deferred Charges ranged from a high of $77000.0 in Q1 2022 to a low of $64000.0 in Q1 2019.
• The 4-year median for Amortization of Deferred Charges is $70000.0 (2020), against an average of $70000.0.
• Across the five-year window, Amortization of Deferred Charges climbed 7.58% in 2020 and rose 5.88% in 2021, its largest moves.
• Viking Therapeutics' Amortization of Deferred Charges stood at $66000.0 in 2019, then grew by 7.58% to $71000.0 in 2020, then gained by 7.04% to $76000.0 in 2021, then increased by 1.32% to $77000.0 in 2022.
• The last three Amortization of Deferred Charges figures came in at $77000.0 (Q1 2022), $76000.0 (Q4 2021), and $75000.0 (Q3 2021), per Business Quant data.